Dose Equivalence: 20mg Torsemide vs 40mg Lasix (Furosemide)
No, 20 mg of torsemide is NOT equivalent to 40 mg of furosemide—the most recent high-quality evidence demonstrates that approximately 40 mg of furosemide equals 10 mg of torsemide (a 4:1 ratio), not the commonly assumed 2:1 ratio.
Evidence-Based Dose Conversion
The 2025 TRANSFORM-Mechanism trial 1—the highest quality mechanistic study available—definitively showed that:
- A 4:1 dose equivalence (40 mg furosemide : 10 mg torsemide) resulted in similar natriuresis
- The commonly used 2:1 conversion (40 mg furosemide : 20 mg torsemide) resulted in substantially greater natriuresis with torsemide (P < 0.001)
- Higher torsemide doses from the 2:1 conversion led to increased neurohormonal activation (renin, aldosterone, norepinephrine) and kidney dysfunction without improving plasma volume or body weight
Clinical Implications
When converting from furosemide to torsemide, use approximately 1/4 the furosemide dose, not 1/2. For example:
- Furosemide 40 mg → Torsemide 10 mg
- Furosemide 80 mg → Torsemide 20 mg
- Furosemide 160 mg → Torsemide 40 mg
Guideline Dosing Recommendations
The 2019 ACC Expert Consensus 2 and 2022 AHA/ACC/HFSA Guidelines 3 provide standard dosing ranges:
Furosemide:
- Initial: 20-40 mg orally once to twice daily
- Maximum: 600 mg/day
Torsemide:
- Initial: 10-20 mg orally once daily
- Maximum: 200 mg/day
These ranges support the 4:1 equivalence ratio rather than 2:1.
Pharmacokinetic Differences
The TRANSFORM-Mechanism trial 1 debunked several assumed advantages of torsemide:
- Kidney bioavailability was actually LOWER with torsemide (17.1%) versus furosemide (24.8%), P < 0.001
- Duration of action was LONGER with furosemide, not torsemide (P ≤ 0.004)
- No meaningful pharmacokinetic/pharmacodynamic advantages for torsemide were observed
Older studies 4, 5 suggested torsemide had longer duration, but these used the incorrect 2:1 dosing ratio, confounding results.
Clinical Outcomes
The large TRANSFORM-HF trial (referenced in 1) showed no difference in clinical outcomes between torsemide and furosemide when used in real-world practice. Recent 2025 Medicare data 6 in 328,640 older adults confirmed:
- Similar composite outcomes (HR 0.97,95% CI: 0.95-0.99)
- Slightly increased acute kidney injury risk with torsemide (HR 1.12,95% CI: 1.10-1.15)
- No difference in hypokalemia or hypovolemia
Critical Pitfalls to Avoid
Do not use the 2:1 conversion ratio (40 mg furosemide = 20 mg torsemide)—this overdoses patients and increases adverse effects without improving volume status
Monitor closely after conversion: Check electrolytes, creatinine, and volume status within 1 week 2, 3
Watch for acute kidney injury: Torsemide carries slightly higher AKI risk, particularly at higher doses 1, 6
Avoid assuming torsemide superiority: Despite theoretical advantages, clinical outcomes are equivalent 1, 7, 6
Practical Conversion Algorithm
When switching from furosemide to torsemide:
- Calculate the 4:1 equivalent dose (divide furosemide dose by 4)
- Start at this dose or slightly lower if concerned about response
- Reassess in 1-7 days: Check weight, volume status, electrolytes, creatinine 2, 3
- Titrate based on response: Double dose if inadequate diuresis 3, 8
- Maximum torsemide 200 mg/day for heart failure 2, 3, 8
The FDA label 8 confirms initial torsemide dosing of 10-20 mg for heart failure, supporting the 4:1 equivalence when converting from typical furosemide doses of 40-80 mg.